Amphastar Pharmaceuticals, Inc.

The company is a biopharmaceutical company that develops, manufactures, and sells complex generic and proprietary injectable, inhalation, and intranasal products, along with active pharmaceutical ingredients (API). It currently manufactures and sells over 25 prescription pharmaceutical products and one over-the-counter product, Primatene MIST®. Its top products by net revenues include BAQSIMI® glucagon nasal powder, Primatene MIST®, glucagon, epinephrine, and lidocaine. In June 2023, the company acquired BAQSIMI®, a nasally administered glucagon for severe hypoglycemia in people with diabetes, available in the United States and 26 international markets. The FDA approved its albuterol sulfate inhalation aerosol in May 2024, launched in August 2024. In August 2025, the FDA approved its iron sucrose injection, USP 50mg/2.5mL, 100mg/5mL, and 200mg/10mL in single-dose vials, launched in August 2025. In December 2025, the FDA approved its teriparatide injection, USP 560mcg/2.24mL single-patient-use prefilled pen, launched in December 2025. In February 2026, the FDA approved its Ipratropium Bromide HFA inhalation aerosol, 17 mcg/actuation, with a planned launch early in the second quarter of 2026. For the years ended December 31, 2025, 2024, and 2023, net revenues were $719.9 million, $732.0 million, and $644.4 million, respectively. Net income for the same periods was $98.1 million, $159.5 million, and $137.5 million, respectively. The company is developing a portfolio of generic abbreviated new drug applications (ANDAs), biologics license applications (BLAs), including biosimilar insulin product candidates, and proprietary product candidates. One ANDA and one biosimilar insulin candidate are currently filed with the FDA.